In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Scrip Asks Innovation

Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players

As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.

Deal Watch Business Strategies

Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU

The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.

Europe Drug Review

Amgen And Synaffix Alliance Could Be Biggest Preclinical ADC Licensing Deal Yet

Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.

Companies Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register